Yoshinao Kobayashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoshinao Kobayashi has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Akiko Eguchi
Biobank Center, Mie University Hospital, Tsu 514-8507, Japan
5 shared publications Mina Tempaku
Department of Gastroenterology and Hepatology Mie University Graduate School of Medicine Tsu Japan
4 shared publicationsMotoh Iwasa
Department of Gastroenterology and Hepatology Mie University Graduate School of Medicine Tsu Japan
4 shared publicationsYoshiyuki Takei
Department of Gastroenterology and Hepatology Mie University Graduate School of Medicine Tsu Japan
4 shared publicationsHiroshi Kitamura
Department of Laboratory Animal Medicine Tohoku University School of Medicine Sendai Japan
3 shared publicationsMasahiko Kaito
Department of Internal Medicine Division of Gastroenterology and Hepatology Mie University School of Medicine, Tsu, Japan
3 shared publications
Latest Publications
- Open Access
- 28 March 2026
- Published by Wiley in Liver International
- Vol. 46 (5) , e70612
The Conjugated Bile Acids Profile Suggests a Novel Liver‐Muscle Axis Associated With Sarcopenia in Chronic Liver Disease
Background: Liver‐related sarcopenia is a devastating systemic complication of chronic liver disease (CLD) driven by mechanisms extending beyond nutritional deficiency. However, the role of liver‐derived humoral factors remains unclear. We utilised a unique cohort of human skeletal muscle biopsies to test the hypothesis that serum conjugated bile acids (C‐BAs) act as key mediators of this liver‐muscle cross‐talk. Methods: Serum and rectus abdominis muscle samples were meticulously collected from 36 CLD patients and 6 non‐CLD controls during elective surgery. Multifidus‐erector spinae and psoas muscle areas were quantified from CT images. Comprehensive correlations were analysed between C‐BAs and molecular markers of muscle inflammation and fibre‐type composition. These findings were supplemented by in vitro validation using GCDCA treatment of C2C12 myotubes. Results: Serum C‐BAs levels were significantly elevated in CLD patients. The liver cirrhosis (LC) group exhibited a significantly smaller multifidus‐erector spinae area (32.06 ± 8.05 cm 2 ) compared to controls (39.78 ± 4.38 cm 2 , p = 0.019). Muscle area loss was strongly correlated with hepatic reserve deterioration (ALBI/ALB) and systemic inflammation (serum IL‐6). Crucially, muscle area was negatively correlated with the ratio of tauro‐C‐BAs ( p < 0.05). Muscle biopsies showed a molecular shift: enrichment of the slow‐twitch fibre marker myosin‐heavy chain 7 (MYH7, type I) and a concomitant reduction of the fast‐twitch marker MYH4 (type IIb), alongside signs of local chronic inflammation ( p < 0.05). The reduction in MYH4 was correlated with glyco‐C‐BAs, a finding replicated in GCDCA‐treated C2C12 myotubes. Conclusions: Elevated C‐BAs may represent a critical, liver‐derived humoral factor associated with the pathological features of liver‐related sarcopenia. C‐BA‐associated muscle mass loss and systemic inflammation are reflected at the molecular level by a shift toward a slow‐twitch phenotype, accumulation of macrophages and altered energy metabolism in muscle biopsies. These findings suggest that C‐BAs may serve as a potentially actionable therapeutic target for mitigating muscle catabolism and improving clinical outcomes in CLD patients.
- 28 March 2026
- Published by Wiley in Liver International
- Vol. 46 (5) , e70612
Open AccessThe Conjugated Bile Acids Profile Suggests a Novel Liver‐Muscle Axis Associated With Sarcopenia in Chronic Liver Disease
Background: Liver‐related sarcopenia is a devastating systemic complication of chronic liver disease (CLD) driven by mechanisms extending beyond nutritional deficiency. However, the role of liver‐derived humoral factors remains unclear. We utilised a unique cohort of human skeletal muscle biopsies to test the hypothesis that serum conjugated bile acids (C‐BAs) act as key mediators of this liver‐muscle cross‐talk. Methods: Serum and rectus abdominis muscle samples were meticulously collected from 36 CLD patients and 6 non‐CLD controls during elective surgery. Multifidus‐erector spinae and psoas muscle areas were quantified from CT images. Comprehensive correlations were analysed between C‐BAs and molecular markers of muscle inflammation and fibre‐type composition. These findings were supplemented by in vitro validation using GCDCA treatment of C2C12 myotubes. Results: Serum C‐BAs levels were significantly elevated in CLD patients. The liver cirrhosis (LC) group exhibited a significantly smaller multifidus‐erector spinae area (32.06 ± 8.05 cm 2 ) compared to controls (39.78 ± 4.38 cm 2 , p = 0.019). Muscle area loss was strongly correlated with hepatic reserve deterioration (ALBI/ALB) and systemic inflammation (serum IL‐6). Crucially, muscle area was negatively correlated with the ratio of tauro‐C‐BAs ( p < 0.05). Muscle biopsies showed a molecular shift: enrichment of the slow‐twitch fibre marker myosin‐heavy chain 7 (MYH7, type I) and a concomitant reduction of the fast‐twitch marker MYH4 (type IIb), alongside signs of local chronic inflammation ( p < 0.05). The reduction in MYH4 was correlated with glyco‐C‐BAs, a finding replicated in GCDCA‐treated C2C12 myotubes. Conclusions: Elevated C‐BAs may represent a critical, liver‐derived humoral factor associated with the pathological features of liver‐related sarcopenia. C‐BA‐associated muscle mass loss and systemic inflammation are reflected at the molecular level by a shift toward a slow‐twitch phenotype, accumulation of macrophages and altered energy metabolism in muscle biopsies. These findings suggest that C‐BAs may serve as a potentially actionable therapeutic target for mitigating muscle catabolism and improving clinical outcomes in CLD patients.
- Open Access
- 29 July 2025
- Published by Wiley in Hepatology Research
- Vol. 55 (11) , 1531-1540
Elevation of Immunoglobulin Free Light Chain and BAFF Levels Associated With Immune Activation Predicts Survival Rates in Chronic Liver Disease
Aims: Elevated serum free light chain (FLC) and B‐cell activating factor (BAFF) levels have been reported to be associated with B‐cell activation and to serve as biomarkers reflecting disease severity in various diseases. However, limited investigation has been conducted in the context of chronic liver disease (CLD), and the aim of this study was to clarify the clinical utility of FLC and BAFF in CLD. Methods: Serum FLC and BAFF levels were measured in healthy individuals (HC; n = 23) and in a cohort of patients with chronic hepatitis (CH; n = 107) and liver cirrhosis (LC; n = 50) of various etiologies and the associations of κ ‐FLC, λ ‐FLC, or BAFF with liver function test results and survival rates were investigated. Results: Serum FLC and BAFF levels increased in parallel with a decrease in hepatic functional reserve capacity, worsening fibrosis, and impaired renal function. Serum κ ‐FLC, λ ‐FLC, or BAFF levels were significantly elevated in CH compared to HC ( p < 0.05, p < 0.001, respectively) and further increased in LC ( p < 0.0001 vs. both HC and CH). The survival rate was significantly lower in patients with high κ ‐FLC, λ ‐FLC, or BAFF compared with patients with low κ ‐FLC, λ ‐FLC, or BAFF ( p < 0.0001, p < 0.01, respectively). Even in the analysis using the multivariable Cox proportional hazards model, both κ ‐FLC and λ ‐FLC were identified as independent prognostic factors. Conclusion: This study specifically demonstrated that serum FLC levels are a strong predictor of survival in patients with CLD and provided important insights into the prognosis of CLD in the context of humoral immunity.
- 29 July 2025
- Published by Wiley in Hepatology Research
- Vol. 55 (11) , 1531-1540
Open AccessElevation of Immunoglobulin Free Light Chain and BAFF Levels Associated With Immune Activation Predicts Survival Rates in Chronic Liver Disease
Aims: Elevated serum free light chain (FLC) and B‐cell activating factor (BAFF) levels have been reported to be associated with B‐cell activation and to serve as biomarkers reflecting disease severity in various diseases. However, limited investigation has been conducted in the context of chronic liver disease (CLD), and the aim of this study was to clarify the clinical utility of FLC and BAFF in CLD. Methods: Serum FLC and BAFF levels were measured in healthy individuals (HC; n = 23) and in a cohort of patients with chronic hepatitis (CH; n = 107) and liver cirrhosis (LC; n = 50) of various etiologies and the associations of κ ‐FLC, λ ‐FLC, or BAFF with liver function test results and survival rates were investigated. Results: Serum FLC and BAFF levels increased in parallel with a decrease in hepatic functional reserve capacity, worsening fibrosis, and impaired renal function. Serum κ ‐FLC, λ ‐FLC, or BAFF levels were significantly elevated in CH compared to HC ( p < 0.05, p < 0.001, respectively) and further increased in LC ( p < 0.0001 vs. both HC and CH). The survival rate was significantly lower in patients with high κ ‐FLC, λ ‐FLC, or BAFF compared with patients with low κ ‐FLC, λ ‐FLC, or BAFF ( p < 0.0001, p < 0.01, respectively). Even in the analysis using the multivariable Cox proportional hazards model, both κ ‐FLC and λ ‐FLC were identified as independent prognostic factors. Conclusion: This study specifically demonstrated that serum FLC levels are a strong predictor of survival in patients with CLD and provided important insights into the prognosis of CLD in the context of humoral immunity.
- Open Access
- 7 October 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humans
Background: Hepatic sarcopenia is one of many complications associated with chronic liver disease (CLD) and has a high mortality rate; however, the liver-muscle axis is not fully understood. Therefore, few effective treatments exist for hepatic sarcopenia, the best of which being branched-chain amino acid (BCAA) supplementation to help increase muscle mass. Our aim was to investigate the molecular mechanism(s) of hepatic sarcopenia focused on bile acid (BA) composition.Methods: The correlation between serum BA levels and psoas muscle mass index (PMI) was examined in 73 CLD patients. Gastrocnemius muscle phenotype and serum BA levels were assessed in CLD rats treated with BCAA. Mouse skeletal muscle cells (C2C12) were incubated with lithocholic acid (LCA), G-protein-coupled receptor 5 (TGR5) agonist or TGR5 antagonist to assess skeletal muscle hypertrophy.Results: In human CLD, serum LCA levels were the sole factor positively correlated with PMI and were significantly decreased in both the low muscle mass group and the deceased group. Serum LCA levels were also shown to predict patient survival. Gastrocnemius muscle weight significantly increased in CLD rats treated with BCAA via suppression of protein degradation pathways, coupled with a significant increase in serum LCA levels. LCA treated C2C12 hypertrophy occurred in a concentration-dependent manner linked with TGR5-Akt pathways based upon inhibition results via a TGR5 antagonist.Conclusions: Our results indicate LCA-mediated skeletal muscle hypertrophy via activation of TGR5-IGF1-Akt signaling pathways. In addition, serum LCA levels were associated with skeletal muscle mass in cirrhotic rats, as well as CLD patients, and predicted overall patient survival.Funding: This research was supported by JSPS KAKENHI Grant Number 22K08011 and 21H02892, and AMED under Grant Number JP21fk0210090 and JP22fk0210115. Maintaining cirrhotic rats were partially supported by Otsuka Pharmaceutical Company.
- 7 October 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Open AccessAssociation of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humans
Background: Hepatic sarcopenia is one of many complications associated with chronic liver disease (CLD) and has a high mortality rate; however, the liver-muscle axis is not fully understood. Therefore, few effective treatments exist for hepatic sarcopenia, the best of which being branched-chain amino acid (BCAA) supplementation to help increase muscle mass. Our aim was to investigate the molecular mechanism(s) of hepatic sarcopenia focused on bile acid (BA) composition.Methods: The correlation between serum BA levels and psoas muscle mass index (PMI) was examined in 73 CLD patients. Gastrocnemius muscle phenotype and serum BA levels were assessed in CLD rats treated with BCAA. Mouse skeletal muscle cells (C2C12) were incubated with lithocholic acid (LCA), G-protein-coupled receptor 5 (TGR5) agonist or TGR5 antagonist to assess skeletal muscle hypertrophy.Results: In human CLD, serum LCA levels were the sole factor positively correlated with PMI and were significantly decreased in both the low muscle mass group and the deceased group. Serum LCA levels were also shown to predict patient survival. Gastrocnemius muscle weight significantly increased in CLD rats treated with BCAA via suppression of protein degradation pathways, coupled with a significant increase in serum LCA levels. LCA treated C2C12 hypertrophy occurred in a concentration-dependent manner linked with TGR5-Akt pathways based upon inhibition results via a TGR5 antagonist.Conclusions: Our results indicate LCA-mediated skeletal muscle hypertrophy via activation of TGR5-IGF1-Akt signaling pathways. In addition, serum LCA levels were associated with skeletal muscle mass in cirrhotic rats, as well as CLD patients, and predicted overall patient survival.Funding: This research was supported by JSPS KAKENHI Grant Number 22K08011 and 21H02892, and AMED under Grant Number JP21fk0210090 and JP22fk0210115. Maintaining cirrhotic rats were partially supported by Otsuka Pharmaceutical Company.
- Open Access
- 1 October 2022
- Published by Japan Institute of Metals in MATERIALS TRANSACTIONS
- Vol. 63 (10) , 1437-1442
Thermodynamics of Oxygen in Molten Nd–Pr–Fe–B Magnet Alloy at High Temperature
Neodymium magnets are widely used as high-performance magnets, but there is a problem that thermal demagnetization is relatively significant because of low Curie temperature. Prevention of oxidation for the Nd-rich phases in the grain boundary phase to which improve coercivity is required. Since oxygen dissolution occurs mainly during melting in alloy preparation process, it is necessary to know the affinity between the molten magnet alloy and oxygen. For the proper understanding of this process in practical use, neodymium magnets are made by replacing some of the Nd with Pr in order to cut costs, so the investigation of the system including Pr is required. In this study, Nd–Pr–Fe–B molten alloys and Nd2O3 crucibles were equilibrated in a sealed system, and oxygen solubility was investigated as a function of alloy compositions. It is confirmed that the affinity between the alloy and oxygen increases as the rare earth concentration increases. On the other hand, little effect of Pr ratio was found on the affinity between the molten Nd–Pr–Fe–B magnet and oxygen. It indicates that Nd and Pr have the similar effects on the affinity of the Nd–Pr–Fe–B magnet to oxygen. In addition, as a way to utilize the thermodynamic data obtained in this report, we did calculations regarding deoxidation to prevent oxidation of the Nd-rich phase.
- 1 October 2022
- Published by Japan Institute of Metals in MATERIALS TRANSACTIONS
- Vol. 63 (10) , 1437-1442
Open AccessThermodynamics of Oxygen in Molten Nd–Pr–Fe–B Magnet Alloy at High Temperature
Neodymium magnets are widely used as high-performance magnets, but there is a problem that thermal demagnetization is relatively significant because of low Curie temperature. Prevention of oxidation for the Nd-rich phases in the grain boundary phase to which improve coercivity is required. Since oxygen dissolution occurs mainly during melting in alloy preparation process, it is necessary to know the affinity between the molten magnet alloy and oxygen. For the proper understanding of this process in practical use, neodymium magnets are made by replacing some of the Nd with Pr in order to cut costs, so the investigation of the system including Pr is required. In this study, Nd–Pr–Fe–B molten alloys and Nd2O3 crucibles were equilibrated in a sealed system, and oxygen solubility was investigated as a function of alloy compositions. It is confirmed that the affinity between the alloy and oxygen increases as the rare earth concentration increases. On the other hand, little effect of Pr ratio was found on the affinity between the molten Nd–Pr–Fe–B magnet and oxygen. It indicates that Nd and Pr have the similar effects on the affinity of the Nd–Pr–Fe–B magnet to oxygen. In addition, as a way to utilize the thermodynamic data obtained in this report, we did calculations regarding deoxidation to prevent oxidation of the Nd-rich phase.
- 1 September 2022
- Published by Taylor & Francis in Journal of Nuclear Science and Technology
- Vol. 60 (4) , 450-459
Double diffusive dissolution model of UO2 pellet in molten Zr cladding
The rapid dissolution of UO2 in molten Zr that could occur during fuel-cladding liquefaction at high temperatures and its kinetics were reformulated considering the convective mass transfer and the scouring effect at the UO2/Zr interface. The mass transfer coefficient of U was obtained as a correlation including the aspect ratio term by computational fluid dynamics (CFD) analysis. To explain the gap between the rapid dissolution rate observed in the experiments and the density-driven convective mass transfer, we introduced an idea in which the eutectic melting at the UO2/Zr interface promotes the solid oxide detachment owing to infiltration of the U-Zr-O liquid into the UO2 grain boundaries (scouring effect). The developed model was validated with UO2-Zr crucible experiments at 2273 and 2373 K. The calculated mass percentage ratios of U/Zr agreed with the measurements, and the transition timings from rapid dissolution stage were consistent with the metallographic observations. Graphical Abstract
- 1 September 2022
- Published by Taylor & Francis in Journal of Nuclear Science and Technology
- Vol. 60 (4) , 450-459
Double diffusive dissolution model of UO2 pellet in molten Zr cladding
The rapid dissolution of UO2 in molten Zr that could occur during fuel-cladding liquefaction at high temperatures and its kinetics were reformulated considering the convective mass transfer and the scouring effect at the UO2/Zr interface. The mass transfer coefficient of U was obtained as a correlation including the aspect ratio term by computational fluid dynamics (CFD) analysis. To explain the gap between the rapid dissolution rate observed in the experiments and the density-driven convective mass transfer, we introduced an idea in which the eutectic melting at the UO2/Zr interface promotes the solid oxide detachment owing to infiltration of the U-Zr-O liquid into the UO2 grain boundaries (scouring effect). The developed model was validated with UO2-Zr crucible experiments at 2273 and 2373 K. The calculated mass percentage ratios of U/Zr agreed with the measurements, and the transition timings from rapid dissolution stage were consistent with the metallographic observations. Graphical Abstract
- Open Access
Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in chronic liver disease rats and humans
[Background & aims] Hepatic sarcopenia is one of many complications associated with chronic liver disease (CLD) and has a high mortality rate, however, the liver-muscle axis is not fully understood. Therefore, few effective treatments exist for hepatic sarcopenia, the best of which being branched-amino acid (BCAA) supplementation to help increase muscle mass. Our aim was to investigate the molecular mechanism(s) of hepatic sarcopenia focused on bile acid (BA) composition. [Methods] Gastrocnemius muscle phenotype and serum BA levels were assessed in CLD rats treated with BCAA. Mouse skeletal muscle cells (C2C12) were incubated with lithocholic acid (LCA), G-protein-coupled receptor 5 (TGR5) agonist or TGR5 antagonist to assess skeletal muscle hypertrophy. The correlation between serum BA levels and psoas muscle area index (PMI) was examined in 73 CLD patients. [Results] Gastrocnemius muscle weight significantly increased in CLD rats treated with BCAA via suppression of protein degradation pathways, coupled with a significant increase in serum LCA levels. LCA treated C2C12 hypertrophy occurred in a concentration-dependent manner linked with TGR5-Akt pathways based upon inhibition results via a TGR5 antagonist. In human CLD, serum LCA levels were the sole factor positively correlated with PMI and were significantly decreased in both the low muscle mass group and the deceased group. Serum LCA levels were also shown to predict patient survival. [Conclusion] Our results indicate LCA-mediated skeletal muscle hypertrophy via activation of TGR5-IGF1-Akt signaling pathways. In addition, serum LCA levels were associated with skeletal muscle mass in cirrhotic rats, as well as CLD patients, and predicted overall patient survival. [Funding] This research was supported by JSPS KAKENHI Grant Number 22K08011 and 21H02892, and AMED under Grant Number JP21fk0210090 and JP22fk0210115.
Open AccessAssociation of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in chronic liver disease rats and humans
[Background & aims] Hepatic sarcopenia is one of many complications associated with chronic liver disease (CLD) and has a high mortality rate, however, the liver-muscle axis is not fully understood. Therefore, few effective treatments exist for hepatic sarcopenia, the best of which being branched-amino acid (BCAA) supplementation to help increase muscle mass. Our aim was to investigate the molecular mechanism(s) of hepatic sarcopenia focused on bile acid (BA) composition. [Methods] Gastrocnemius muscle phenotype and serum BA levels were assessed in CLD rats treated with BCAA. Mouse skeletal muscle cells (C2C12) were incubated with lithocholic acid (LCA), G-protein-coupled receptor 5 (TGR5) agonist or TGR5 antagonist to assess skeletal muscle hypertrophy. The correlation between serum BA levels and psoas muscle area index (PMI) was examined in 73 CLD patients. [Results] Gastrocnemius muscle weight significantly increased in CLD rats treated with BCAA via suppression of protein degradation pathways, coupled with a significant increase in serum LCA levels. LCA treated C2C12 hypertrophy occurred in a concentration-dependent manner linked with TGR5-Akt pathways based upon inhibition results via a TGR5 antagonist. In human CLD, serum LCA levels were the sole factor positively correlated with PMI and were significantly decreased in both the low muscle mass group and the deceased group. Serum LCA levels were also shown to predict patient survival. [Conclusion] Our results indicate LCA-mediated skeletal muscle hypertrophy via activation of TGR5-IGF1-Akt signaling pathways. In addition, serum LCA levels were associated with skeletal muscle mass in cirrhotic rats, as well as CLD patients, and predicted overall patient survival. [Funding] This research was supported by JSPS KAKENHI Grant Number 22K08011 and 21H02892, and AMED under Grant Number JP21fk0210090 and JP22fk0210115.
- Open Access
- 1 March 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 135, 111181
Branched-chain amino acids and l-carnitine attenuate lipotoxic hepatocellular damage in rat cirrhotic liver
- 1 March 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 135, 111181
Open AccessBranched-chain amino acids and l-carnitine attenuate lipotoxic hepatocellular damage in rat cirrhotic liver
- 1 September 2012
- Published by AIP Publishing in Journal of Applied Physics
- Vol. 112 (5) , 053712
Electrical and heat conduction mechanisms of GeTe alloy for phase change memory application
GeTe alloy has drawn much attention as one of the promising candidates for phase change memory application. In this work, the electrical resistivities and thermal conductivities of GeTe alloy have been determined as functions of temperature by the four-terminal method and hot strip method, respectively. The electrical resistivity increases and the thermal conductivity decreases monotonically with increasing temperature, and thus it is likely that free electron dominates the thermal conduction. The electrical resistivity increases slowly with time during holding at 773 K, and the thermal conductivity decreases corresponding to the change of the electrical resistivity, which suggests that small amount of high temperature phase might exist in the samples.
- 1 September 2012
- Published by AIP Publishing in Journal of Applied Physics
- Vol. 112 (5) , 053712
Electrical and heat conduction mechanisms of GeTe alloy for phase change memory application
GeTe alloy has drawn much attention as one of the promising candidates for phase change memory application. In this work, the electrical resistivities and thermal conductivities of GeTe alloy have been determined as functions of temperature by the four-terminal method and hot strip method, respectively. The electrical resistivity increases and the thermal conductivity decreases monotonically with increasing temperature, and thus it is likely that free electron dominates the thermal conduction. The electrical resistivity increases slowly with time during holding at 773 K, and the thermal conductivity decreases corresponding to the change of the electrical resistivity, which suggests that small amount of high temperature phase might exist in the samples.
- 20 March 2006
- Published by Elsevier in Acta Materialia
- Vol. 54 (9) , 2441-2449
Simulation of the influence of phosphorus on the prior austenite grain size of high-impurity steels
- 20 March 2006
- Published by Elsevier in Acta Materialia
- Vol. 54 (9) , 2441-2449
Simulation of the influence of phosphorus on the prior austenite grain size of high-impurity steels
- Open Access
- 23 December 2004
- Published by Wolters Kluwer Health in Hepatology
- Vol. 41 (1) , 217-218
Dietary fiber decreases ammonia levels in patients with cirrhosis
- 23 December 2004
- Published by Wolters Kluwer Health in Hepatology
- Vol. 41 (1) , 217-218
Open AccessDietary fiber decreases ammonia levels in patients with cirrhosis